Literature DB >> 32374178

Meta-analysis of immunogenicity and safety of human rabies vaccination under Zagreb and Essen regimens.

Ting Li1, Xin Wang1, Hongbin Cheng1.   

Abstract

Aim: To assess the immunogenicity and safety of rabies vaccination under the Zagreb and Essen regimens by performing a meta-analysis.
Methods: Electronic databases were searched for eligible studies. Risk ratios and weighted mean differences with 95% CIs were used to calculate estimates.
Results:  A total of 18 studies were included. Rabies virus neutralizing antibody concentration was comparable between the two regimens at D7 and 14. No significant differences were observed in seroconversion rates from D14 and 42. Incidence of fever was higher in Zagreb group (risk ratio: 1.55 [1.37-1.76]); but no significant differences were present for other common adverse events.
Conclusion: Rabies vaccination under the Zagreb regimen was noninferior to the Essen regimen in immunogenicity and had an acceptable safety profile.

Entities:  

Keywords:  Zagreb regimen; immunogenicity; meta-analysis; rabies vaccine; safety

Mesh:

Substances:

Year:  2020        PMID: 32374178     DOI: 10.2217/cer-2019-0202

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  2 in total

1.  Research trends in rabies vaccine in the last three decades: a bibliometric analysis of global perspective.

Authors:  Tauseef Ahmad; Muhammad Khan; Manal Abdulaziz Murad; Mukhtiar Baig; Bibi Nazia Murtaza; Muhammad Mumtaz Khan; Harapan Harapan; Jin Hui
Journal:  Hum Vaccin Immunother       Date:  2021-05-04       Impact factor: 3.452

2.  Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis.

Authors:  Shi-Yuan Wang; Jin-Fang Sun; Pei Liu; Li Luo; Jing-Xin Li; Feng-Cai Zhu; Xu-Xiang Shen; Fan-Yue Meng
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.